**NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES**Calgary, Alberta--(Newsfile Corp. - January 7, 2026) - Reconnaissance Energy Africa Ltd. (TSXV: RECO) (OTCQX: RECAF) (FSE: 0XD) (NSX: REC) (the "Company" or "ReconAfrica" or "Recon") announces that, in connection with its previously announced overnight marketed, listed issuer financing exemption private placement offering of units of the Company (each, a "Unit"), it has increased the size of the offering d ...

Core Points - MoonLake Immunotherapeutics has announced an underwritten offering of 7,142,857 Class A ordinary shares at a price of $10.50 per share, aiming to raise approximately $75 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about November 6, 2025, pending customary closing conditions [1]. - Leerink Partners is acting as the sole bookrunning manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used alongside existing cash and marketable securities to fund the research and development of sonelokimab and for general corporate purposes [2]. Group 3: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody, targeting inflammatory diseases with significant unmet needs [5]. - The company addresses conditions such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis, which affect millions globally [5].

Core Viewpoint - Rezolute, Inc. has successfully closed an underwritten offering of 24,940,769 shares of common stock at a price of $3.25 per share, raising approximately $96.9 million for research and development, corporate expenses, and working capital needs [1][2]. Group 1: Offering Details - The offering included 4,153,846 shares from the underwriters' option and pre-funded warrants for up to 6,905,385 shares at an offering price of $3.2490 per warrant [1]. - The offering attracted participation from both new and existing investors, including notable firms such as Federated Hermes Kaufmann Funds and Blackstone Multi-Asset Investing [2]. - Guggenheim Securities served as the sole book-running manager, with BTIG, H.C. Wainwright & Co., and Jones as lead managers [3]. Group 2: Private Placement - In addition to the offering, existing investors have committed to purchase up to $4.2 million in shares in a private placement at the same offering price, expected to close around May 7, 2025 [4]. Group 3: Company Overview - Rezolute, Inc. is a late-stage biopharmaceutical company focused on developing therapies for rare diseases, particularly targeting hypoglycemia caused by hyperinsulinism [7]. - The company's antibody therapy, ersodetug, has demonstrated significant benefits in clinical trials for treating congenital and tumor-related hypoglycemia [7].